Current Area: News-> Celebrex (Pfizer) Class Action

Pfizer Agrees to Cease Advertising Celebrex

On December 20, 2004, Pfizer Inc. agreed to immediately discontinue advertising Celebrex after studies indicated an elevated risk of heart attacks, strokes and serious cardiovascular problems.

Health Canada has issued a warning that daily doses of 400 mg. and 800 mg. of Celebrex increases cardiovascular risks.  It notes that a cancer prevention study by the National Cancer Institute in the United States showed increased risks for serious cardiovascular events.  At the 400 mg. daily dose the risk was 2.5 times higher and at the 800 mg. daily dose the risk was 3.4 times higher. 

Pfizer has stopped a trial it was sponsoring using a 400 mg. daily dose of Celebrex.  Celebrex has been available in 100 mg., 200 mg. and 400 mg. doses.

More than 26 million people have taken Celebrex since was first approved by the U.S. Food and Drug Administration in December 1998.

Annual sales of Celebrex have exceeded $2 billion.

Like Vioxx, Celebrex is a COX-2 anti-inflammatory drug.  In September 2004 Merk & Co. withdrew Vioxx from the market entirely.

McPhadden Samac Merner Barry has commenced a class action against Pfizer Canada Inc. and Pfizer Inc. of the United States.  Attached is a copy of the issued Statement of Claim.

Back to top